Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.6 PLN | -1.82% | -4.33% | -15.48% |
Business Summary
Sales per Business
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Small Molecule Therapies
100.0
%
| 39 | 100.0 % | 47 | 100.0 % | +20.32% |
Sales per region
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
European Union Countries
88.9
%
| 25 | 63.2 % | 42 | 88.9 % | +69.25% |
Other Countries
11.0
%
| 14 | 36.5 % | 5 | 11.0 % | -63.73% |
Poland
0.1
%
| 0 | 0.3 % | 0 | 0.1 % | -64.15% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 31/12/06 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/22 |
Chief Operating Officer | 38 | 31/12/12 | |
Chief Tech/Sci/R&D Officer | - | 31/12/06 | |
Vatnak Vat-Ho
PRN | Corporate Officer/Principal | - | 25/04/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 13/06/23 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Rafal Chwast
BRD | Director/Board Member | - | - |
Piotr Romanowski
CHM | Chairman | - | 31/12/18 |
Director/Board Member | 64 | 30/09/19 | |
Peter Smith
BRD | Director/Board Member | - | 13/06/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,120,148 | 14,971,356 ( 64.75 %) | 8 ( 0.000035 %) | 64.75 % |
Company contact information
Sector
Sales per region
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.48% | 282M | |
-1.42% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.76% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-9.89% | 16.36B | |
+7.67% | 14.39B | |
+36.37% | 12.37B |
- Stock Market
- Equities
- RVU Stock
- Company Ryvu Therapeutics S.A.